EYLEA, also known as aflibercept, is a vascular endothelial growth factor (VEGF) inhibitor used in the treatment of several eye diseases. It is used to treat wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), diabetic retinopathy (DR) and macular edema following retinal vein occlusion (RVO). EYLEA is administered via intravitreal injections directly into the eye. 

The Global EYLEA Drug Market Size is expected to witness high growth driven by rising prevalence of retinal disorders in an aging population. EYLEA being the leading therapy approved for wet AMD and DME has established strong market presence